SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 ...
SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies SOMERVILLE, Mass., Dec. 1, 2025 ...
Generate:Biomedicines (Generate), a technology company founded at the intersection of machine learning, biological engineering, and medicine, announced it plans to initiate two global phase 3 clinical ...
Engineering student team applies SoterGenius® to real industrial workflows to uncover ergonomic hazards and recommend ...
From reference-grade loudspeakers and AV processors to subwoofers and headphones, 2025 delivered standout audio and home ...
TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback